For how many years can the Nexplanon (etonogestrel) subdermal implant remain in place?

Nexplanon Duration of Use

Nexplanon (etonogestrel implant) is FDA-approved to remain in place for 3 years, after which it must be removed or replaced. 1, 2, 3

FDA-Approved Duration

• The etonogestrel implant provides contraceptive protection for 3 years from insertion, as established by the American Academy of Pediatrics and CDC guidelines 1
• After 3 years, the device should be removed and replaced with a new implant if continued contraception is desired 1, 2

Contraceptive Effectiveness During Approved Period

• Nexplanon demonstrates exceptional efficacy with a failure rate of less than 0.05% during the 3-year approved duration, making it one of the most effective reversible contraceptive methods available 1, 2
• Both typical-use and perfect-use failure rates remain below 1% throughout the approved 3-year period 1

Evidence for Extended Use Beyond 3 Years

While not FDA-approved, emerging research demonstrates continued effectiveness:

• Recent studies show no documented pregnancies during years 4 and 5 of etonogestrel implant use 2, 4, 5
• Serum etonogestrel levels remain above the ovulation threshold (90 pg/mL) through 5 years in all body mass index categories 4
• The calculated failure rate at 4 years is 0 per 100 woman-years (95% CI: 0-1.48) and at 5 years is 0 per 100 woman-years (95% CI: 0-2.65) 4
• One case report documented contraceptive effectiveness even 6 years after insertion 6

Important Caveat About Extended Use

Extended use beyond 3 years is not currently recommended for standard clinical practice, despite promising research data 2. This remains an area of ongoing investigation 7, 8.

Clinical Management Algorithm

At 3 years post-insertion:

1. Schedule removal appointment
2. Counsel patient on replacement options
3. Remove implant and immediately insert new device if continued contraception desired (no backup method needed) 1

If patient requests extended use beyond 3 years:

• Inform patient this is off-label use
• Discuss that research supports effectiveness but FDA approval is only for 3 years
• Document shared decision-making
• Consider body mass index (median etonogestrel levels are lowest in obese women during year 4) 4

Key Clinical Considerations

• Backup contraception is required for 7 days after initial insertion if placed >5 days after menstrual bleeding started 1
• The 84% continuation rate at 1 year reflects high user satisfaction despite irregular bleeding patterns 1, 2
• Drug interactions with hepatic enzyme inducers (efavirenz, nevirapine, most protease inhibitors) can reduce effectiveness; alternative or additional contraception is required 2
• Irregular bleeding does not indicate contraceptive failure and patients should be reassured accordingly 2